BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alavi M, Law MG, Valerio H, Grebely J, Amin J, Hajarizadeh B, Selvey C, George J, Dore GJ. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. Journal of Hepatology 2019;71:281-8. [DOI: 10.1016/j.jhep.2019.04.014] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 He S, Lockart I, Alavi M, Danta M, Hajarizadeh B, Dore GJ. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. Aliment Pharmacol Ther 2020;51:34-52. [DOI: 10.1111/apt.15598] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
2 Cameron JK, Baade P. Projections of the future burden of cancer in Australia using Bayesian age-period-cohort models. Cancer Epidemiol 2021;72:101935. [PMID: 33838461 DOI: 10.1016/j.canep.2021.101935] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Valencia J, Lazarus JV, Ceballos FC, Troya J, Cuevas G, Resino S, Torres-Macho J, Ryan P. Differences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as point-of-care. Liver Int 2021. [PMID: 34767680 DOI: 10.1111/liv.15095] [Reference Citation Analysis]
4 Hutchinson SJ, Valerio H, McDonald SA, Yeung A, Pollock K, Smith S, Barclay S, Dillon JF, Fox R, Bramley P, Fraser A, Kennedy N, Gunson RN, Templeton K, Innes H, McLeod A, Weir A, Hayes PC, Goldberg D. Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study. Gut 2020;69:2223-31. [PMID: 32217640 DOI: 10.1136/gutjnl-2019-320007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
5 Dore GJ, Martinello M, Alavi M, Grebely J. Global elimination of hepatitis C virus by 2030: why not? Nat Med 2020;26:157-60. [PMID: 32047317 DOI: 10.1038/s41591-019-0706-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
6 Cotte L, Hocqueloux L, Lefebvre M, Pradat P, Bani-sadr F, Huleux T, Poizot-martin I, Pugliese P, Rey D, Cabié A, Chirouze C, Drobacheff-thiébaut C, Foltzer A, Bouiller K, Hustache-mathieu L, Lepiller Q, Bozon F, Babre O, Brunel AS, Muret P, Chevalier E, Jacomet C, Laurichesse H, Lesens O, Vidal M, Mrozek N, Aumeran C, Baud O, Corbin V, Goncalvez E, Mirand A, brebion A, Henquell C, Lamaury I, Fabre I, Curlier E, Ouissa R, Herrmann-storck C, Tressieres B, Receveur MC, Boulard F, Daniel C, Clavel C, Roger PM, Markowicz S, Chellum Rungen N, Merrien D, Perré P, Guimard T, Bollangier O, Leautez S, Morrier M, Laine L, Boucher D, Point P, Cotte L, Ader F, Becker A, Boibieux A, Brochier C, Brunel-dalmas F, Cannesson O, Chiarello P, Chidiac C, Degroodt S, Ferry T, Godinot M, Livrozet JM, Makhloufi D, Miailhes P, Perpoint T, Perry M, Pouderoux C, Roux S, Triffault-fillit C, Valour F, Charre C, Icard V, Tardy JC, Trabaud MA, Ravaux I, Ménard A, Belkhir AY, Colson P, Dhiver C, Madrid A, Martin-degioanni M, Meddeb L, Mokhtari M, Motte A, Raoux A, Toméi C, Tissot-dupont H, Poizot-martin I, Brégigeon S, Zaegel-faucher O, Obry-roguet V, Laroche H, Orticoni M, Soavi MJ, Ressiot E, Ducassou MJ, Jaquet I, Galie S, Colson H, Ritleng AS, Ivanova A, Debreux C, Lions C, Rojas-rojas T, Cabié A, Abel S, Bavay J, Bigeard B, Cabras O, Cuzin L, Dupin de Majoubert R, Fagour L, Guitteaud K, Marquise A, Najioullah F, Pierre-françois S, Pasquier J, Richard P, Rome K, Turmel JM, Varache C, Atoui N, Bistoquet M, Delaporte E, Le Moing V, Makinson A, Meftah N, Merle de Boever C, Montes B, Montoya Ferrer A, Tuaillon E, Reynes J, Lefèvre B, Jeanmaire E, Hénard S, Frentiu E, Charmillon A, Legoff A, Tissot N, André M, Boyer L, Bouillon MP, Delestan M, Goehringer F, Bevilacqua S, Rabaud C, May T, Raffi F, Allavena C, Aubry O, Billaud E, Biron C, Bonnet B, Bouchez S, Boutoille D, Brunet-cartier C, Deschanvres C, Gaborit BJ, Grégoire A, Grégoire M, Grossi O, Guéry R, Jovelin T, Lefebvre M, Le Turnier P, Lecomte R, Morineau P, Reliquet V, Sécher S, Cavellec M, Paredes E, Soria A, Ferré V, André-garnier E, Rodallec A, Pugliese P, Breaud S, Ceppi C, Chirio D, Cua E, Dellamonica P, Demonchy E, De Monte A, Durant J, Etienne C, Ferrando S, Garraffo R, Michelangeli C, Mondain V, Naqvi A, Oran N, Perbost I, Carles M, Klotz C, Maka A, Pradier C, Prouvost-keller B, Risso K, Rio V, Rosenthal E, Touitou I, Wehrlen-pugliese S, Zouzou G, Hocqueloux L, Prazuck T, Gubavu C, Sève A, Giaché S, Rzepecki V, Colin M, Boulard C, Thomas G, Cheret A, Goujard C, Quertainmont Y, Teicher E, Lerolle N, Jaureguiberry S, Colarino R, Deradji O, Castro A, Barrail-tran A, Yazdanpanah Y, Landman R, Joly V, Ghosn J, Rioux C, Lariven S, Gervais A, Lescure FX, Matheron S, Louni F, Julia Z, Le Gac S, Charpentier C, Descamps D, Peytavin G, Duvivier C, Aguilar C, Alby-laurent F, Amazzough K, Benabdelmoumen G, Bossi P, Cessot G, Charlier C, Consigny PH, Jidar K, Lafont E, Lanternier F, Leporrier J, Lortholary O, Louisin C, Lourenco J, Parize P, Pilmis B, Rouzaud C, Touam F, Valantin MA, Tubiana R, Agher R, Seang S, Schneider L, Palich R, Blanc C, Katlama C, Bani-sadr F, Berger JL, N’guyen Y, Lambert D, Kmiec I, Hentzien M, Brunet A, Romaru J, Marty H, Brodard V, Arvieux C, Tattevin P, Revest M, Souala F, Baldeyrou M, Patrat-delon S, Chapplain JM, Benezit F, Dupont M, Poinot M, Maillard A, Pronier C, Lemaitre F, Morlat C, Poisson-vannier M, Jovelin T, Sinteff JP, Gagneux-brunon A, Botelho-nevers E, Frésard A, Ronat V, Lucht F, Rey D, Fischer P, Partisani M, Cheneau C, Priester M, Mélounou C, Bernard-henry C, de Mautort E, Fafi-kremer S, Delobel P, Alvarez M, Biezunski N, Debard A, Delpierre C, Gaube G, Lansalot P, Lelièvre L, Marcel M, Martin-blondel G, Piffaut M, Porte L, Saune K, Robineau O, Ajana F, Aïssi E, Alcaraz I, Alidjinou E, Baclet V, Bocket L, Boucher A, Digumber M, Huleux T, Lafon-desmurs B, Meybeck A, Pradier M, Tetart M, Thill P, Viget N, Valette M; Dat’AIDS Study Group. Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012–2018. Clinical Infectious Diseases 2021. [DOI: 10.1093/cid/ciaa1940] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Clark PJ, Valery PC, Strasser SI, Weltman M, Thompson AJ, Levy M, Leggett B, Zekry A, Rong J, Angus P, George J, Bollipo S, McGarity B, Sievert W, Macquillan G, Tse E, Nicoll A, Wade A, Chu G, Harding D, Cheng W, Farrell G, Roberts SK. Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort. Dig Dis Sci 2022. [PMID: 35552941 DOI: 10.1007/s10620-022-07483-y] [Reference Citation Analysis]
8 Marshall AD, Hopwood M, Grebely J, Treloar C. Applying a diffusion of innovations framework to the scale-up of direct-acting antiviral therapies for hepatitis C virus infection: Identified challenges for widespread implementation. International Journal of Drug Policy 2020;86:102964. [DOI: 10.1016/j.drugpo.2020.102964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Vegas JJ, Flores-Herrera J, Latasa P, Garrido-Estepa M. Reduction in hepatitis C-related hospitalizations after the implementation of the Strategic Plan for Tackling Hepatitis C in the Spanish National Health System: regional level differences. J Viral Hepat 2021;28:859-69. [PMID: 33599365 DOI: 10.1111/jvh.13491] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Klein MB. Hepatitis C virus elimination: time for disruptive innovation. J Int AIDS Soc 2019;22:e25360. [PMID: 31347280 DOI: 10.1002/jia2.25360] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Burton A, Tataru D, Driver RJ, Bird TG, Huws D, Wallace D, Cross TJS, Rowe IA, Alexander G, Marshall A; HCC-UK/BASL/NCRAS Partnership Steering Group. Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation. JHEP Rep 2021;3:100232. [PMID: 33748727 DOI: 10.1016/j.jhepr.2021.100232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Mate-Cano I, Alvaro-Meca A, Ryan P, Resino S, Briz V. Epidemiological trend of hepatitis C-related liver events in Spain (2000-2015): A nationwide population-based study. Eur J Intern Med 2020;75:84-92. [PMID: 32143898 DOI: 10.1016/j.ejim.2020.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Martinello M, Hajarizadeh B, Dore GJ. Hepatitis C elimination in Australia: progress and challenges. Medical Journal of Australia 2020;212:362-3. [DOI: 10.5694/mja2.50584] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
14 Crespo J, Lázaro P, Blasco AJ, Aguilera A, García-Samaniego J, Eiros JM, Calleja JL, García F. Hepatitis C reflex testing in Spain in 2019: A story of success. Enferm Infecc Microbiol Clin (Engl Ed) 2021;39:119-26. [PMID: 32451150 DOI: 10.1016/j.eimc.2020.03.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Rashidi A, Higgs P, Carruthers S. Factors affecting hepatitis C treatment intentions among Aboriginal people in Western Australia: a mixed-methods study. Aust Health Rev 2020;44:755-62. [PMID: 32854816 DOI: 10.1071/AH19194] [Reference Citation Analysis]
16 Kåberg M, Weiland O. Hepatitis C elimination - Macro-elimination. Liver Int 2020;40 Suppl 1:61-6. [PMID: 32077600 DOI: 10.1111/liv.14352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Semmler G, Meyer EL, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, Bauer D, Chromy D, Simbrunner B, Scheiner B, Stättermayer AF, Pinter M, Schöfl R, Russo FP, Greenfield H, Schwarz M, Schwarz C, Gschwantler M, Alonso López S, Manzano ML, Ahumada A, Bañares R, Pons M, Rodriguez-Tajes S, Genesca J, Lens S, Trauner M, Ferenci P, Reiberger T, Mandorfer M. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J Hepatol 2021:S0168-8278(21)02234-0. [PMID: 34871626 DOI: 10.1016/j.jhep.2021.11.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
18 Garrido-estepa M, Latasa P, Flores-herrera J, García Comas L. Hepatitis C and hepatitis C-related advanced liver disease hospitalisation trends before and after the Strategic Plan for Tackling Hepatitis C in the National Health System. European Journal of Gastroenterology & Hepatology 2021;33:1307-15. [DOI: 10.1097/meg.0000000000001841] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Cunningham EB, Wheeler A, Hajarizadeh B, French CE, Roche R, Marshall AD, Fontaine G, Conway A, Valencia BM, Bajis S, Presseau J, Ward JW, Degenhardt L, Dore GJ, Hickman M, Vickerman P, Grebely J. Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2022:S2468-1253(21)00471-4. [PMID: 35303490 DOI: 10.1016/S2468-1253(21)00471-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 McDonald SA, Pollock KG, Barclay ST, Goldberg DJ, Bathgate A, Bramley P, Dillon JF, Fraser A, Innes HA, Kennedy N, Morris J, Went A, Hayes PC, Hutchinson SJ. Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis. J Viral Hepat 2020;27:270-80. [PMID: 31696575 DOI: 10.1111/jvh.13232] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
21 Dore GJ. Elimination of hepatitis C in Australia by 2030: a decade and counting. Aust Prescr 2021;44:36-7. [PMID: 33911328 DOI: 10.18773/austprescr.2021.003] [Reference Citation Analysis]
22 Park H, Jiang X, Song HJ, Lo Re V 3rd, Childs-Kean LM, Lo-Ciganic WH, Cook RL, Nelson DR. The Impact of Direct-Acting Antiviral Therapy on End-Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders. Hepatology 2021;74:566-81. [PMID: 33544904 DOI: 10.1002/hep.31732] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Innes H, McDonald SA, Hamill V, Yeung A, Dillon JF, Hayes PC, Went A, Fraser A, Bathgate A, Barclay ST, Janjua N, Goldberg DJ, Hutchinson SJ. Declining incidence of hepatitis C related hepatocellular carcinoma in the era of interferon-free therapies: a population-based cohort study. Liver Int 2021. [PMID: 34951109 DOI: 10.1111/liv.15143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Lafferty L, Rance J, Dore GJ, Grebely J, Lloyd AR, Treloar C; SToP-C Study Group. Hepatitis C treatment as prevention in the prison setting: Assessments of acceptability of treatment scale up efforts by prison correctional and health personnel. Int J Drug Policy 2021;98:103379. [PMID: 34311138 DOI: 10.1016/j.drugpo.2021.103379] [Reference Citation Analysis]
25 Grebely J, Tran L, Degenhardt L, Dowell-Day A, Santo T, Larney S, Hickman M, Vickerman P, French C, Butler K, Gibbs D, Valerio H, Read P, Dore GJ, Hajarizadeh B. Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis. Clin Infect Dis 2021;73:e107-18. [PMID: 32447375 DOI: 10.1093/cid/ciaa612] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
26 Dasgupta P, Henshaw C, Youlden DR, Clark PJ, Aitken JF, Baade PD. Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:171. [PMID: 32185125 DOI: 10.3389/fonc.2020.00171] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
27 Valerio H, Alavi M, Law M, Tillakeratne S, Amin J, Janjua NZ, Krajden M, George J, Matthews GV, Hajarizadeh B, Degenhardt L, Grebely J, Dore GJ. High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. J Hepatol 2021;74:293-302. [PMID: 32931879 DOI: 10.1016/j.jhep.2020.08.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
28 Tu T, Rodrigo C, Strasser SI, Bowden DS, MacLachlan JH, Drummer HE. The Inaugural Australian Centre for Hepatitis Virology Public Panel Discussion on Viral Hepatitis Research-Lessons in Scientific Community Outreach. Viruses 2021;13:1838. [PMID: 34578419 DOI: 10.3390/v13091838] [Reference Citation Analysis]
29 Politi J, Guerras JM, Donat M, Belza MJ, Ronda E, Barrio G, Regidor E. Favorable impact in hepatitis C-related mortality following free access to direct-acting antivirals in Spain. Hepatology 2022;75:1247-56. [PMID: 34773281 DOI: 10.1002/hep.32237] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Gibney KB, MacLachlan J, Coutts R, Higgins N, Strachan J. Incidence of Invasive Pneumococcal Disease Higher Among People Notified With Markers of Hepatitis C Virus Infection: Population-based Surveillance in Victoria, Australia, 2001-2017. Clin Infect Dis 2021;72:e319-25. [PMID: 32750118 DOI: 10.1093/cid/ciaa1110] [Reference Citation Analysis]
31 Ciupkeviciene E, Petkeviciene J, Sumskiene J, Dragunas G, Dabravalskis S, Kreivenaite E, Telksnys T, Urbonas G, Kupcinskas L. Hepatitis C Virus Epidemiology in Lithuania: Situation before Introduction of the National Screening Programme. Viruses 2022;14:1192. [DOI: 10.3390/v14061192] [Reference Citation Analysis]